Want to see GB:BSFA full AI Analyst Report?
Top Page
BSF Enterprise PLC
(LSE:BSFA)
Select Model
Select Model
Rating:47Neutral
Price Target:
1.00 p
▼(-13.04% Downside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial performance (continued losses, negative gross profit, and ongoing cash burn), only partly offset by a low-debt balance sheet and some improvement in cash burn. Technicals are mildly supportive in the near term but longer-term trends remain negative. Valuation provides little support due to the negative P/E and lack of dividend yield.
Positive Factors
Rapid Revenue Growth
Revenue increased from 12.9k in 2023 to 52.8k in 2025, with triple-digit growth in 2025. This stronger commercial scale can support future operating leverage and broaden the business base over the next several quarters, even though profitability has not yet been achieved.
Negative Factors
Persistent Unprofitability
Gross profit has remained negative and net margins materially negative in every year with revenue. That shows current sales do not cover the cost base, leaving the business dependent on future scaling or cost improvement before growth can translate into durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
Revenue increased from 12.9k in 2023 to 52.8k in 2025, with triple-digit growth in 2025. This stronger commercial scale can support future operating leverage and broaden the business base over the next several quarters, even though profitability has not yet been achieved.
Read all positive factors
BSF Enterprise PLC (BSFA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.29M
Dividend YieldN/A
Average Volume (3M)2.38M
Price to Earnings (P/E)―
Beta (1Y)3.78
Revenue Growth112.02%
EPS Growth31.51%
CountryUK
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding203,849,440
10 Day Avg. Volume1,804,536
30 Day Avg. Volume2,382,395
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.46
Price to Sales (P/S)75.11
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BSF Enterprise PLC Business Overview & Revenue Model
Company Description
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company develops and commercializes cell-based tissue engineered solutions, including lab-grown leather, cultivated meat, and corneal repair technologies. The principal activity of ...
BSF Enterprise PLC Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.06K | 52.84K | 57.82K | 12.94K | 0.00 | 0.00 |
| Gross Profit | -125.04K | -127.47K | -26.64K | -86.55K | -160.50K | 0.00 |
| EBITDA | -1.29M | -1.10M | -1.68M | -1.46M | -905.76K | -58.22K |
| Net Income | -1.28M | -1.11M | -1.67M | -1.50M | -930.04K | -58.43K |
Balance Sheet | ||||||
| Total Assets | 3.47M | 3.01M | 3.50M | 5.26M | 4.03M | 401.45K |
| Cash, Cash Equivalents and Short-Term Investments | 60.17K | 149.02K | 637.66K | 2.32M | 1.06M | 359.87K |
| Total Debt | 482.32K | 0.00 | 78.05K | 156.93K | 231.88K | 0.00 |
| Total Liabilities | 1.71M | 289.02K | 305.07K | 401.63K | 449.47K | 36.63K |
| Stockholders Equity | 1.76M | 2.72M | 3.19M | 4.86M | 3.58M | 364.82K |
Cash Flow | ||||||
| Free Cash Flow | -642.81K | -1.02M | -1.60M | -1.44M | -677.86K | -85.19K |
| Operating Cash Flow | -600.62K | -1.01M | -1.59M | -1.38M | -667.24K | -85.19K |
| Investing Cash Flow | -41.76K | -9.92K | -12.02K | -64.85K | 1.75K | 0.00 |
| Financing Cash Flow | 363.60K | 529.69K | -78.88K | 2.70M | 1.37M | 0.00 |
BSF Enterprise PLC Technical Analysis
Positive
1.15
Price Trends
1.04
Positive
1.23
Negative
1.48
Negative
Market Momentum
>-0.01
Negative
56.28
Neutral
55.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BSFA, the sentiment is Positive. The current price of 1.15 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 1.04, and below the 200-day MA of 1.48, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 56.28 is Neutral, neither overbought nor oversold. The STOCH value of 55.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BSFA.
BSF Enterprise PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £4.22M | 4.42 | 15.97% | 0.26% | ― | ― | |
47 Neutral | £2.29M | -1.14 | -57.16% | ― | 112.02% | 31.51% | |
45 Neutral | £2.17M | -1.51 | -43.66% | ― | ― | 83.53% | |
44 Neutral | £2.43M | -5.64 | -17.10% | 1.86% | ― | 68.42% | |
43 Neutral | £1.71M | -0.37 | -54.65% | ― | 2950.00% | -273.53% |
* Healthcare Sector Average
GB:BSFA
BSF Enterprise PLC
1.13
-2.13
-65.38%
GB:BLU
Blue Star Capital
4.25
-10.00
-70.18%
GB:TRUE
Braveheart Investment
3.10
0.95
44.19%
GB:MFAI
Pires Investments
0.33
-0.43
-56.67%
GB:PRIM
Primorus Investments
3.40
-0.40
-10.53%
GB:CGO
Contango Holdings Plc
0.70
-0.13
-15.15%
BSF Enterprise PLC Corporate Events
Business Operations and Strategy
BSF Enterprise Secures Key U.S. Patent for ETSYL Collagen Technology
Positive
Sep 23, 2026
BSF Enterprise’s subsidiary 3D Bio-Tissues has secured a Notice of Allowance from the U.S. Patent and Trademark Office for its ETSYL-branded collagen production technology, protecting proprietary methods that use the bioactive peptide palmit...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
BSF Enterprise Gains FCA Approval for Prospectus to Support Warrant Exercises and Share Admission
Positive
Sep 8, 2026
BSF Enterprise PLC has secured approval from the Financial Conduct Authority for a new prospectus that establishes a long-term regulatory framework for the potential exercise of existing warrants and convertible securities over the next 12 months....
Delistings and Listing ChangesPrivate Placements and Financing
BSF Enterprise reduces debt as Indigo converts £100k of loan notes into shares
Positive
Aug 25, 2026
BSF Enterprise PLC has received a notice from Indigo Capital Investments to convert £100,283 of its £1m convertible loan notes into equity. The company will satisfy the conversion by issuing 10,000,000 new ordinary shares of 1 penny each...
Business Operations and Strategy
BSF Enterprise strikes SCHAKAU deal to push lab-grown leather into ultra-luxury cars and robotics
Positive
Aug 17, 2026
BSF Enterprise has signed a strategic partnership with German consultancy SCHAKAU Managementberatung to commercialise its lab-grown leather in the ultra-luxury European automotive market and to advance biological human-interface technologies for r...
Business Operations and StrategyProduct-Related Announcements
BSF Enterprise Grants Global Exclusive Rights to ETSYL Peptide in Luxury Skincare Deal
Positive
Aug 11, 2026
BSF Enterprise PLC has signed heads of terms for a worldwide, exclusive commercialisation and supply partnership for its proprietary bioactive peptide ETSYL with SCHAKAU Managementberatung GmbH in the cosmetics and luxury beauty sectors. SCHAKAU i...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
BSF Enterprise Strikes US Joint Venture to Launch T-Rex Leather in Luxury Market
Positive
Aug 3, 2026
BSF Enterprise PLC has signed non-binding Heads of Terms with US ethical luxury brand operator IMPOSTER LLC to form a 50/50 joint venture aimed at launching its T-Rex Leather in the North American luxury market. The JV will initially focus on smal...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
BSF Enterprise Advances Lab-Grown Leather and Biotech Portfolio as Funding Bolsters 2026 Growth
Positive
Jun 30, 2026
BSF Enterprise reported unaudited interim results for the six months to 31 March 2026, highlighting strategic progress across its lab-grown leather, cell therapy and corneal implant subsidiaries. The group continued to shift from intensive researc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.